Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer

Table 1 Values and missing values of patients according to each characteristic, n (%)

All patients (n = 409)
Characteristics	Values	Missing values
Age	409 (100)	0 (0)
Gender	409 (100)	0 (0)
Stage	409 (100)	0 (0)
T	369 (90.2)	40 (9.8)
N	365 (89.2)	44 (10.8)
M	409 (100)	0 (0)
Differentiation	330 (80.7)	79 (19.3)
HER-2	316 (77.3)	93 (22.7)
APR	406 (99.3)	3 (0.7)
NLR	409 (100)	0 (0)
CAR	399 (97.6)	10 (2.4)
PLR	409 (100)	0 (0)
LMR	409 (100)	0 (0)
CEA	337 (82.4)	72 (17.6)
CA-199	333 (81.4)	76 (18.6)
CA-125	312 (76.3)	97 (23.7)

The missing values show the number of patients without relevant characteristics. T: T stage; N: N stage; M: M stage; HER-2: Human epidermal growth factor receptor 2; APR: Alkaline phosphatase to prealbumin ratio; NLR: Neutrophil to lymphocyte ratio; CAR: C-reactive protein to albumin ratio; PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; CEA: Carcinoembryonic antigen; CA-199: Glycoprotein antigen 199; CA-125: Carbohydrate antigen 125.

Table 2 Clinical characteristics of patients in the alkaline phosphatase to prealbumin ratio-low and -high groups, n (%)

Characteristics	APR-low (n = 199)	APR-high (n = 207)	P Value
Age (yr)
< 60	94 (47.2)	71 (34.3)	0.0080b
≥ 60	105 (52.8)	136 (65.7)
Average age	58.7	62.1
Gender
Female	35 (17.6)	54 (26.1)	0.0385a
Male	164 (82.4)	153 (73.9)
Stage
Stage 1	70	20	< 0.005b
Stage 2	35	29
Stage 3	75	120
Stage 4	19	38
Stage 1 + 2	105 (52.8)	49 (23.7)	< 0.005b
Stage 3 + 4	94 (47.2)	158 (76.3)
T stage
T1	57	19	< 0.005b
T2	29	9
T3	9	19
T4	96	128
T1 + 2	86 (45.1)	28 (16.0)	< 0.005b
T3 + 4	105 (54.9)	147 (84.0)
N stage
N0	90	46	< 0.005b
N1	37	32
N2	30	35
N3	31	61
N0 + 1	127 (67.6)	78 (44.8)	< 0.005b
N2 + 3	61 (32.4)	96 (55.2)
M stage
M0	181 (91.0)	169 (81.6)	0.0065b
M1	18 (9.0)	38 (18.4)
Differentiation
L/ML	98	108	0.1378
M	62	45
H/HM	9	5
HER-2
0	101	94	0.9450
1	26	28
2	23	24
3	8	9

^aP < 0.05.

^bP < 0.01. APR: Alkaline phosphatase to prealbumin ratio; HER-2: Human epidermal growth factor receptor 2; L: Indicates low differentiation; ML: Moderate-low differentiation; M: Moderate differentiation; HM: High-moderate differentiation; H: High differentiation.

Table 3 Median neutrophil and lymphocyte ratio, C-reactive protein to albumin ratio, platelet to lymphocyte ratio, lymphocyte to monocyte ratio, and tumor marker levels

Characteristics	APR-Low group	APR-High group	P Value
NLR	1.87	2.09	< 0.005b
CAR	0.02	0.07	< 0.005b
PLR	133.50	162.50	< 0.005b
LMR	4.57	3.79	< 0.005b
CEA	2.42	3.00	0.053
CA-199	11.52	13.74	0.0374a
CA-125	10.14	12.76	0.0020b

^aP < 0.05.

^bP < 0.01. APR: Alkaline phosphatase to prealbumin ratio; NLR: Neutrophil to lymphocyte ratio; CAR: C-reactive protein to albumin ratio; PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; CEA: Carcinoembryonic antigen; CA-199: Glycoprotein antigen 199; CA-125: Carbohydrate antigen 125.